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Abstract: Drug toxicity is, unfortunately, a significant problem in children both in the hospital and in
the community. Drug toxicity in children is different to that seen in adults. At least one in 500 children
will experience an adverse drug reaction each year. For children in hospital, the risk is far greater
(one in ten). Additionally, different and sometimes unique adverse drug reactions are seen in the
paediatric age groups. Some of the major cases of drug toxicity historically have occurred in neonates.
It is important that we understand the mechanism of action of adverse drug reactions. Greater
understanding alongside rational prescribing should hopefully reduce drug toxicity in children in
the future.
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1. Introduction
Drug toxicity is a common clinical problem in paediatric patients of all ages. An adverse drug
reaction (ADR) is defined by the World Health Organization (WHO) as “a response to a medicine
which is noxious and unintended and which occurs at doses normally used in man” [1]. At least one
in 500 children will experience an ADR each year [2]. One in ten children in hospital will experience
an ADR [3]. It is impossible to prevent all ADRs, however there is a need to try and minimise drug
toxicity. This can be achieved by using medicines rationally and prescribing medicines only when
there is an evidence base that suggests they are effective. Additionally, one can learn lessons from
some of the major ADRs that have occurred in paediatric patients. By understanding the mechanisms
of actions of drug toxicity, one can then hopefully recognise potential drug toxicity associated with
certain medicines. The aim of this paper is to review the mechanisms of drug toxicity using historical
examples of adverse drug reactions in children. Such information will help health professionals use
medicines more safely in the future.
2. Percutaneous Drug Toxicity
There have been several ADRs that have occurred in neonates and young infants due to
percutaneous absorption of a variety of compounds [4]. Neonates and young infants have a higher
surface area to weight ratio than children so medicines that are administered topically result in greater
relative exposure. Transcutaneous diffusion of small molecules is also facilitated in this age group by a
thinner stratum corneum and a greater water content in the dermis. In 1886 a letter was published in the
British Medical Journal highlighting the toxicity of aniline dye in newborn infants in a workhouse [5].
Seventeen babies developed cyanosis due to methaemoglobinemia following cutaneous exposure to
the aniline dye which was used to stamp the name of the institution (Marylebone Workhouse, UK) on
their nappies. Percutaneous toxicity is not restricted to neonates. It has also been reported in infants
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and children. Thirty six infants and young children died in France in the early eighties following
contamination of a talc baby powder with hexachlorophene [6]. Other examples of percutaneous
toxicity include toxicity with iodine [7], alcohol [8], and nicotine [9] (Table 1).
Table 1. Mechanisms of adverse drug reactions in paediatric patients.
Mechanism Drug ADR
Percutaneous absorption
Aniline dye Methaemoglobinaemia
Hexachlorophene Neurotoxicity
Iodine Hypothyroidism
Alcohol Metabolic acidosis
Nicotine Nausea/vomiting
Bilirubin displaced from albumin Sulfisoxazole Kernicterus
Impaired metabolism Chloramphenicol Grey baby syndrome
Abnormal metabolism Valproic acid Hepatotoxicity
Excipient toxicity Benzyl alcohol Multi-organ failure
Diethylene glycol
Drug interaction
Ceftriaxone and calcium
containing solutions Calcium precipitation
Lamotrigine and valproic acid Skin reactions
Polypharmacy Valproic acid Hepatotoxicity
Unknown
Salicylates Reye’s syndrome
Propofol Metabolic acidosis and lipaemia
Vigabatrin Visual field defects
Corticosteroids Growth suppression Neurotoxicity
Macrolides Pyloric stenosis
ADR: adverse drug reaction.
‚ Percutaneous drug toxicity is more likely to be a significant problem in neonates and infants, than
other age groups.
3. Protein Binding
In 1956 a clinical trial in the USA reporting two different antibiotic regimes in sick neonates
described a higher mortality rate associated with an increase in kernicterus among one of the
groups [10]. The authors were unable to explain their findings but fortunately reported the increased
mortality associated with the use of a combination of penicillin and sulfisoxazole (a sulphonamide).
The other group received oxytetracycline. The infants who received the combination of penicillin and
sulfisoxazole were at greater risk of kernicterus and the associated seizures, opisthotonus, spasticity,
and poor feeding.
Subsequent studies several years later demonstrated that sulphonamides are highly protein
bound [11]. They, therefore, displace bilirubin from albumin causing an increase in the free fraction
of bilirubin in the plasma. It is the free fraction of bilirubin (unconjugated) that is responsible for the
development of kernicterus. Protein binding of medicines is not usually a clinical problem but in sick
preterm infants with high bilirubin levels it is clearly a significant issue. It is important, therefore, to
avoid highly protein bound medicines in neonates.
‚ Avoid highly protein bound medicines in sick neonates (eg.sulphonamides, ceftriaxone).
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4. Ontogeny of Drug Metabolism
In 1959, the death of three newborn infants in Cincinnati, USA was reported following the
administration of chloramphenicol [12]. The babies developed abdominal distension, vomiting,
cyanosis, and cardiovascular collapse (grey baby syndrome). A year later it was demonstrated that
the metabolism of chloramphenicol is impaired in neonates [13]. This impaired drug metabolism
illustrates the importance of reducing the dose of chloramphenicol in neonates. At the time that
chloramphenicol was initially used in neonates there had been no studies of drug metabolism in the
newborn infant. Subsequent studies have shown that many of the metabolic pathways (oxidation and
conjugation) are significantly reduced in neonates, with enzyme activity significantly lower in preterm
neonates than in term neonates [14,15].
‚ Drug doses in relation to body weight need to be lower in neonates than in infants and children.
‚ Mechanisms of drug metabolism should be assessed in all age groups in which a drug is likely to
be used in practice, and doses altered depending on findings.
5. Excipient Toxicity
All medicines contain excipients. Excipients are chemical substances that increase the solubility,
stability or palatability of medicines. One of the earliest examples of excipient toxicity was the use of
diethylene glycol as a solvent to make sulphonamides more soluble in water [16,17]. Diethylene glycol
is a highly toxic substance and was responsible for the death of many children and adults in the USA
in the 1930s [16].
Benzyl alcohol is an excipient that is used for its antibacterial properties and is a constituent
of ampoules of sodium chloride and water that are administered intravenously. Unfortunately, the
solutions contained 0.9% benzyl alcohol which proved to be toxic in premature neonates. The neonates
were receiving multiple injections of benzyl alcohol-containing solutions through catheter flushes and
reconstitution or dilution of medications [18]. The toxicity occurred in neonates because they have a
reduced capacity to metabolise alcohol. Additionally, the amount of alcohol administered in relation
to their body weight will have been far greater than that administered to a 70 kg adult. The exact
number of deaths associated with the use of benzyl alcohol in ampoules of sodium chloride and water
is unknown.
An intravenous vitamin E preparation (E-Ferol) was used to prevent retinopathy of prematurity
in preterm neonates in several centres in the USA in 1983 [19]. Thirty-eight deaths were reported and
the intravenous vitamin E preparation was withdrawn. It was suggested that excipients used were
responsible for the toxicity [20]. These are examples from the last century, but a recent European study
of potentially harmful excipients in neonatal medicines has shown it may be an ongoing problem [21].
The increasing research into the effect of excipients is to be welcomed and can only improve the safety
of the use of medicines in children [21].
‚ All medicines contain excipients, which are added to the active product and may be toxic. When
adverse events occur then excipients should be considered as well as the constituent drug.
6. Drug Interactions
There have been several case reports of calcium precipitation in the lungs of neonates and young
infants in association with the use of ceftriaxone and calcium containing solutions [22,23]. The exact
mechanism of this interaction is uncertain. Enzyme inhibition by one drug may result in an enhanced
effect of another drug, e.g., erythromycin inhibiting CYP3A4 metabolism of midazolam, resulting
in enhanced sedation [24]. Drug interactions are a potential problem in children receiving long
term medication, especially antiepileptic drugs [25]. An example of a drug interaction involving
anti-epileptic drugs is the use of lamotrigine in conjunction with valproic acid. The main ADR
associated with lamotrigine is a skin reaction [26]. In the majority of cases the skin reactions are
mild. There is a risk however of Stevens-Johnson syndrome or toxic epidermal necrolysis. The use
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of valproic acid in conjunction with lamotrigine significantly increases the risk of skin reactions [26].
The mechanism for this interaction is also unknown. An awareness that there is always a risk of
a drug interaction, when prescribing more than one medicine, should always be present in the
prescribers mind.
‚ Check for possible drug interactions in a formulary before prescribing multiple medications.
‚ Avoid using lamotrigine in combination with valproic acid whenever possible.
7. Polypharmacy
Polypharmacy significantly increases the risk of drug toxicity [26–28] and therefore should be
avoided wherever possible. The concept of using more than one medicine to treat a condition in order
to minimise drug toxicity was initially developed for the management of pain relief [29]. This use
of polypharmacy was designed to reduce the dosage of opioid analgesics which are known to be
associated with significant toxicity. The use of polypharmacy in relation to analgesia has been shown to
be effective both in terms of insuring adequate pain relief and also in relation to reducing toxicity [29].
Unfortunately, polypharmacy has also been introduced in other therapeutic areas where it increases
the risk of toxicity.
Valproic acid is a highly effective anticonvulsant and is the drug of choice for many children
with epilepsy. Hepatotoxicity is a rare ADR associated with sodium valproate. Case reports of
hepatoxicity in association with valproic acid were reported in the late 1970s. A review of 37 cases of
fatal hepatoxicity in the USA identified three major risk factors: polytherapy, developmental delay and
an age of under three years [30] A review of individual case safety reports to the WHO collaborating
centre for international drug monitoring in Uppsala identified hepatotoxicity as the most likely cause
of death in association with valproic acid in children [27]. Again polytherapy was a significant risk
factor and the risk of hepatotoxicity appeared to be greatest in children aged six years and below, but
can occur at any age [27].
‚ Polytherapy with valproic acid increases the risk of hepatotoxicity.
8. Unknown Mechanisms
There are numerous cases of drug toxicity where the mechanism is unknown. In these situations
drug toxicity can be minimised by avoiding the use of certain medications for certain conditions.
8.1. Salicylates and Reye’s Syndrome
Reye’s syndrome is a life-threatening illness with drowsiness, seizures, hypoglycaemia and liver
failure. It was first described in 1963 and a possible link between Reye’s syndrome and salicylates was
postulated in 1965 [31]. Giles noted that 15 of 31 cases of Reye’s syndrome had received salicylates prior
to admission [31]. The association between Reye’s syndrome and the use of salicylates as an antipyretic
during a viral infection was confirmed in 1980 [32]. Subsequently salicylates were contraindicated as
an antipyretic and analgesic in children ď12 years in many countries. This has led to a large reduction
in the incidence of Reye’s syndrome [33]. Subsequently it has been reported in children between the
ages of 12 and 16 and so is no longer recommended in this age group as an antipyretic [34]. Although
the mechanism of action is unknown, by avoiding the use of salicylates in children with a viral illness
one has been able to dramatically reduce the incidence of Reye’s syndrome.
‚ Avoid salicylates as an antipyretic in children of all ages.
8.2. Propofol and Metabolic Acidosis
Propofol is a short acting anaesthetic agent that is safe and effective as an anaesthetic agent. It was
used as an intravenous sedative in critically ill children due to its short acting properties. Children
receiving propofol as a sedative agent received considerably higher cumulative doses of propofol than
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when used as an anaesthetic agent. Unfortunately, several children died following the use of propofol
as a sedative agent [35]. The children developed severe metabolic acidosis and lipaemia. Although
the mechanism responsible for the metabolic acidosis remains uncertain, toxicity is more likely with
higher doses [36].
‚ Avoid the use of propofol as a sedative in critically ill children.
8.3. Vigabatrin and Visual Field Defects
Vigabatrin is an antiepileptic drug that is particularly effective in the management of infantile
spasms. Shortly after its initial use, however, constrictions of the visual fields were described in both
adults and children [37]. The risk of visual field defects is thought to be lower in children than in adults.
Corticosteroids are now the first line treatment for children with infantile spasms but vigabatrin may
be necessary in children who do not respond to corticosteroids. Monitoring for visual field defects is
important in these children.
‚ Vigabatrin use in children with infantile spasms may be justified but monitoring for visual field
defects is essential.
8.4. Corticosteroids and Growth
Corticosteroids are used in a wide variety of medical conditions. They have been shown to be
effective in the management of asthma. A particular problem associated with their use in children is
their adverse effect on growth. The majority of children receiving corticosteroids for the management
of their asthma receive inhaled corticosteroids in order to minimise toxicity. Growth suppression is,
however, still a potential problem despite the administration of corticosteroids by the inhaled route and
children with symptoms and those taking high doses should be screened for adrenal suppression [38].
‚ Be aware of the potential adverse effect on growth of inhaled corticosteroids.
8.5. Corticosteroids and the Developing Brain
The corticosteroid dexamethasone has been used in preterm neonates with hyaline membrane
disease in order to reduce the risk of chronic lung disease. Although effective in reducing the risk of
chronic lung disease, post-natal dexamethasone has resulted in an increase in adverse neurological
outcomes [39–41]. The mechanism of neurotoxicity is uncertain. The neurotoxicity however does
highlight the increased susceptibility of preterm neonates to drug toxicity that is not found in other
age groups.
‚ Be aware that preterm neonates may experience different adverse drug reactions to other
age groups.
8.6. Macrolides and Pyloric Stenosis
Erythromycin is an old antibiotic that has been used extensively. Its association with pyloric
stenosis was first reported in the 1970s [42]. Subsequently, others confirmed the association [43]. It
has since been recognised as an uncommon adverse drug reaction associated with erythromycin.
Azithromycin is a newer macrolide antibiotic that is widely used. Its advantages over erythromycin
are that it can be administered once daily and is less likely to cause vomiting. It too, however, appears
to be associated with the development of pyloric stenosis [44,45].
‚ Be aware that some adverse drug reactions may be a risk with the class of drug used rather than
just the individual drug.
9. Rational Use of Medicines
Medicines are essential for the management of many diseases and illnesses effecting children. It
is important, however, to recognise that many medicines are used inappropriately [46]. Antibiotics
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are the most extensively used drug in children. Two recent studies in France and Serbia reported that
in both countries, antibiotics are over-prescribed [47,48]. Over 85% of children in Serbia with a viral
upper respiratory tract infection received an antibiotic [48]. Over half the children in France received
an antibiotic each year. Other drugs were also used irrationally. In France, one in five children under
the age of two years received domperidone [47]. The inappropriate use of domperidone and protein
pump inhibitors for infants with mild gastro-oesophageal reflux has been highlighted recently [49].
The rational use of medicines in children has been a neglected issue in high income countries
as well as countries with limited resources [50]. The exclusive use of cough and cold medication in
infants in the United States of America was associated with significant toxicity including fatalities [51].
It is important to ensure that there is an evidence base for the use of every single medicine that is
prescribed to children.
‚ Avoid prescribing unnecessary medicines.
10. Conclusions
Drug toxicity should always be considered as a cause of a child’s symptoms and the risk of
possible harm should be considered before prescribing a medicine. Discussion should always take
place with children and their parents about the risk of the medicines they are being prescribed and
their common adverse affects. By using medicines in a rational manner, drug toxicity can hopefully
be minimised.
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